NKCC1 is currently gaining increased attention as a possible therapeutic target for treating a myriad of CNS disorders [10], and the search for brain-permeable and specific NKCC1 drugs is heating up [11,12,13]. This evidence concerns the gene SLC12A2 and central nervous system disorder.